MPMerve Pamukçuoğlu

Merve Pamukçuoğlu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Merve Pamukçuoğlu has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Endocrine Complications in Long-Term Survivors of Allogeneic Hematopoietic Stem Cell Transplantation: Prevalence and Risk Factors

    by Burcu Aslan Candir, Elif Suyani, Zeynep Arzu Yegin, Zubeyde Nur Ozkurt, Merve Pamukcuoglu, Zeynep Sahika Aki, Gulsan Turkoz Sucak

    Amaç: Allojenik hematopoietik kök hücre nakli (AKHN), çeşitli hematolojik hastalıklar için potansiyel olarak küratif bir tedavi seçeneğidir. Ancak uzun dönem sağ kalan hastalar, yaşam kalitesini belirgin şekilde bozabilen geç başlangıçlı komplikasyonlardan, özellikle endokrin disfonksiyonlardan, giderek daha fazla etkilenmektedir. Bu çalışmanın amacı, AKHN sonrası en az bir yıl hastalıksız sağ kalan hastalarda geç dönem endokrin komplikasyonların sıklığını ve risk faktörlerini belirlemektir. Gereç ve Yöntemler: Tek bir üçüncü basamak merkezde AKHN uygulanmış 79 hastayı içeren retrospektif bir kohort analizi yapıldı. Nakil sonrası ilk yıl içinde hastalık nüksü gelişen ve kaybedilen hastalar çalışmaya dahil edilmedi. Demografik ve nakille ilişkili özellikler, graft-versus-host hastalığı, immünsüpresif tedaviler ve endokrin sonuçlara ait veriler analiz edildi. Nakil öncesinde ilgili endokrin hastalığı bulunan hastalar, ilgili endokrin komplikasyon gelişim risk analizlerinden dışlandı. Risk faktörleri tek değişkenli istatistiksel yöntemlerle değerlendirildi. Bulgular: Medyan takip süresi 38 aydı. Yeni gelişen endokrin komplikasyonlar hastaların önemli bir kısmında saptandı: dislipidemi (%77.3), osteopeni/osteoporoz (%58.2), hipogonadizm (%27.8), tiroid disfonksiyonu (hipotiroidi veya hipertiroidi: %36.2) ve hipertansiyon (%33.5). Anlamlı risk faktörleri arasında kadın cinsiyet, kortikosteroid maruziyeti, kısa süreli siklosporin kullanımı ve akut graft-versus-host hastalığı yer aldı. Avasküler nekroz %13.9 oranında saptandı ve bifosfonat, mikofenolat mofetil ve steroid kullanımı ile ilişkili bulundu. Sonuç: Endokrin komplikasyonlar, uzun dönem AKHN sağ kalanlarında oldukça yaygındır. Özellikle belirli risk faktörlerine sahip hastalarda düzenli ve kapsamlı endokrin izlem büyük önem taşımaktadır. Bu komplikasyonların erken tanınması ve yönetimi, bu hasta grubunda yaşam kalitesini artırabilir.

  • Open Access

    Clinical Associations of Osteoporosis in BCR::ABL1 Negative Myeloproliferative Neoplasms

    by Mürüvvet Seda Aydin, Simten Dagdas, Mehmet Sezgin Pepeler, Gülten Korkmaz, Aysel Alper, Elif Açıkgöz, Tugce Nur Bektas, Merve Pamukçuoğlu, Funda Ceran, Gulsum Ozet

    Background/Aim: Osteoporosis can be seen in some hematologic diseases, such as BCR::ABL1‐negative myeloproliferative neoplasms. The incidence and prevalence of osteoporosis and osteopenia in BCR::ABL1‐negative MPN are not very well known. Materials and Methods: Patients diagnosed with one of the classical BCR::ABL1‐negative myeloproliferative neoplasms, such as essential thrombocythemia, polycythemia vera, and myelofibrosis, were included in the study. Due to the retrospective design, a matched control group was not available, and comparisons with the general population were made for contextual interpretation. Results: Ninety‐four patients were included. Fifty‐eight (61.7%) patients had osteopenia, and 16 (17%) patients had osteoporosis according to femoral dual energy X‐ray absorptiometry (DXA) measurements. Fifty‐three (58.9%) patients had osteopenia, and 27 (30%) patients had osteoporosis according to lumbar DXA measurements. When both femur and lumbar DXA measurements were evaluated together, 67 (71.3%) patients had osteopenia and 31 (33%) patients had osteoporosis. In patients over 50 years of age, these frequencies were found to be 71.4% for osteopenia and 37.7% for osteoporosis. Osteopenia was significantly associated with female sex, cytoreduction, and longer disease duration ( p < 0.05). In the multivariate analysis, female sex was found to be an independent risk factor for osteopenia ( p = 0.009, OR: 3.70, 95% CI: 1.394–9.833). Osteoporosis was significantly associated with disease subtype, female sex, age, and no antiaggregant use ( p < 0.05). In the multivariate analysis, older age ( p = 0.044, OR: 1.04, 95% CI: 1.001–1.083) was found to be an independent risk factor for osteoporosis. Conclusion: Patients with BCR::ABL1‐negative classical myeloproliferative neoplasms have a higher risk of osteopenia/osteoporosis compared to the general population. DXA measurements should be performed, especially in female patients and in patients of advanced age.

  • Open Access

    Ruxolitinib-Treated Myeloproliferative Neoplasms: Real-World Infectious Outcomes and Preventive Practices from a Single Center

    by Muruvvet Seda Aydin, Gulten Korkmaz, Merve Pamukcuoglu, Hatice Rahmet Guner, Funda Ceran, Simten Dagdas, Gulsum Ozet

    Background: Ruxolitinib has been associated with an increased risk of viral infections and tuberculosis reactivation in patients with Philadelphia chromosome-negative myeloproliferative neoplasm. However, data regarding screening practices and prophylactic approaches in routine clinical care remain limited. Objective: To describe latent tuberculosis screening, antiviral prophylaxis practices, and infectious outcomes in ruxolitinib-treated patients with myeloproliferative neoplasm at a single center. Methods: Thirty patients with Philadelphia chromosome-negative myeloproliferative neoplasm treated with ruxolitinib were included in this retrospective single-center study. Results: The median duration of ruxolitinib therapy was 20.1 months. Latent tuberculosis screening was performed in nearly all patients, and isoniazid prophylaxis was administered to five individuals according to screening results. No tuberculosis reactivation occurred during follow-up. Antiviral prophylaxis was administered to 56.6% of patients. One patient developed herpes zoster during treatment, and two experienced recurrent oral herpes. Exploratory analyses did not identify statistically significant clinical factors associated with recurrent oral herpes or antiviral prophylaxis initiation. Conclusion: This study provides a descriptive real-world account of infectious outcomes and institutional screening and management practices in ruxolitinib-treated patients with Philadelphia chromosome-negative myeloproliferative neoplasm. Larger prospective studies are required to further clarify optimal screening and prophylactic strategies.

  • Akut Miyeloid Lösemi Hastalarında Kemik İliği Fibrozisinin Sağkalım Üzerine Olan Etkisi

    by Mehmet Sezgin Pepeler, Merve Pamukçuoğlu, Eyüp Can Alemdar, Fahir Öztürk, Gülten Korkmaz, Mürüvvet Seda Aydin, Emel İşLeyen, Merve Ecem Erdoğan Yön, Funda Ceran, Simten Dağdaş, et al.

  • Open Access

    The infection rate in new diagnosis and relapsed/refractory multiple myeloma patients who had bortezomib-based chemotherapy and relationship between development of infection and lymphocyte/monocyte ratio

    by Merve Pamukcuoglu, Nuran Ahu Baysal, Mehmet Sezgin Pepeler

    Objectives: Multiple Myeloma (MM) is a disease caused by the clonal proliferation of plasma cells. In recent years, proteozom inhibitors, immunomodulatory agents and monoclonal antibodies have been used in the treatment of MM. In this study, the relation of bortezomib, one of the proteozoma inhibitors used in the treatment of MM, with the development of infection was investigated. Methods: We retrospectively evaluated 56 patients who had MM treated with bortezomib-based regimen. We tried to determine the relationship between infection with immunoglobulin G levels at the time of diagnosis, lymphocyte absolute values at the time of diagnosis, lymphocyte absolute values at the time of chemotherapy, neutrophil absolute value at the time of chemotherapy, lymphocyte absolute values at the time of infection, monocyte absolute value at the time of infection, and the lymphocyte/monocyte (L/M) ratio at the time of infection. The effects of L/M ratio on progression free survival (PFS) and overall survival (OS) were also examined. Results: Thirty (53.6%) of the 56 patients were newly diagnosed, 26 (46.4%) of 56 patients were relapsed/refractory MM. The bortezomib-based regimen was given to all patients. Of the 56 patients included in the study, 21 (37.5%) were female, 35 were male (62.5%). The ages of the patients was 28-79 years (median: 58.5 years). No infection attack was observed in 31 (55.4%) patients. Disease stage (R-ISS) (p = 0.032), presence or absence of co-morbid disease (p = 0.035), disease status during an infection attack (p < 0.01), lymphocytopenia at the time of chemotherapy (p = 0.003), absolute value of lymphocytopenia at the time of infection attack (p < 0.01) and L/M ratio (p < 0.01) had a significant relation with development of infection. Lymphocytopenia at the time of infection attack (p < 0.01, OR 0.05). Conclusions: It was determined that L/M ratio has an effect on OS and it is also an independent factor on the development of infection. OS was decreasing and the risk of developing infection was increasing, when the L/M ratio was low.

  • Open Access

    The Relationship between Conditioning Regimen with Viral and Fungal Infections in Allogeneic Hematopoietic Stem Cell Transplantation

    by Pamukcuoglu Merve, City Hospital Of Ankara- Hematology And Bone Marrow Stem Cell Transplantation

    Background: Infections are one of the most important factors that adversely affect the transplantation process at hematopoietic stem cell transplantation (HSCT). Quality of life and even the loss of patients due to infection may result in the failure of the HSCT. While the studies in the literature were mostly related to bacterial infections in HSCT, the viral and fungal infections were evaluated. The relationship between viral and fungal infections and the types of conditioning regimens used in HSCT was investigated. Methods: Three hundred fifthy one (351) patients who had allogeneic HSCT were performed. The viral and / or fungal infections and conditioning regimens were determined from the medical records. The conditioning regimens were evaluated in two groups as myeloablative and non-myeloablative. We aimed to determine the statistical relationship between viral and fungal infections and type of conditioning regimen. Results: Of the 351 patients, 104 had CMV infection, 4 had parvovirus infection, and 87 had fungal infection. Myeloablative regimen was used in 226 of 351 patients and non-myeloablative regimen was used in 125 patients. There was no significant relationship between the type of conditioning regimen and CMV, parvovirus and fungal infections. Conclusion: The lack of a significant relationship between the type of conditioning regimen and the viral and fungal infections during HSCT provides the clinician with the choice of the conditioning regimen. However; we need to do more studies with larger case series and also relationship between the type of conditioning regimen and viral and fungal infections should be more clearly demonstrated. Keyworlds: Viral infection, Fungal infection, Allogeneic hematopoetic stem cell transplantation.

  • Hiperlökositoz Bulgusu ile Başvuran Akut Myelositer Lösemili Olgularda Lökoferez, Hidroksiüre ve Steroid Tedavilerinin Geriye Dönük Olarak Birbiri ile Karşılaştırılması

    by Merve Pamukcuoglu, Mehmet Sezgin Pepeler

    Amaç: Akut myeloid lösemili olguların bir kısmı lökositoz ve hatta eşlik eden lökositaz bulguları ile başvurmaktadır. Hiperlökositoz ve lökositaz bulguları olan hastalarda indüksiyon tedavisi öncesi sitoredüktif tedavi rutin pratikte uygulanan bir yöntemdir. Bu çalışmada; hiperlökositoz ile başvuran akut myeloid lösemili olgularda hidroksiüre sitoredüksiyon tedavisi ile hidroksiüre/lökoferez/steroid sitoredüksiyon tedavilerinin karşılaştırılması amaçlanmıştır. Materyal Metod: Çalışmaya hiperlökositoz bulgusu ile başvuran 40 akut myeloid lösemili olgu alınmıştır. Hastaların dosya bilgileri geriye dönük taranmış ve demografik özellikleri ile aldıkları sitoredüktif tedaviler belirlenmiştir. Kırk hastadan 30’una hidroksiüre sitoredüksiyon tedavisi, 10 hastaya ise hidroksiüre/lökoferez/steroid sitoredüksiyon tedavileri verilmiştir. Bulgular: Hastaların ortanca yaşı 48,5 / yıl (en düşük-en yüksek: 18-75/yıl) idi. Altmış yaş altında 30 (%75) hasta, 60 yaş üstünde 10 (%25) hasta vardı. Yirmibir (% 52,5) hasta erkek, 19 (%47,5) hasta kadın idi. Hastaların başvuru anındaki beyaz küre değerlerinin ortancası 86.x109/L (düşük/yüksek: 50.x109/L -300.x109/L) idi. Sitoredüksiyon tedavisi sonrası hastaların beyaz küre değerinin ortancası 71.x109/L (düşük/yüksek: 38.x109/L -95.x109/L) idi. Tanı anında yapılan kemik iliği aspırasyonundaki blast oranı ortanca %82,75 (düşük/yüksek;%20-%100) idi. Sitoredüksiyon ve birinci indüksiyon sonrası yapılan kontrol kemik iliği aspırasyonundaki blast oranlarının ortancası %5,12 (düşük/yüksek;%0-%100) idi.Hidroksiüre/lökoferez/steroid alan kolda sadece hidroksiüre alan kola göre beyaz küre değerlerinin daha iyi kontrol altına alındığı görüldü (p:0,001). Ancak sitoredüksiyon tedavi kollarından hiçbirinin kemik iliğinde blast oranını azaltması yönünde anlamlı ilişkisi olmadığı tespit edildi (p: >0,05). Sonuç: Hidroksiüre/ lökoferez/steroid kolunun sadece hidroksiüre koluna göre çevre kanı beyaz küre sayısını daha etkin düşürdüğü sonucuna varılmıştır.

  • Kolorektal kanserlerde vitamin D reseptör ekspresyonunun kolorektal kanserlerde evre ile ilişkili ve prognoz üzerine etkisi

    by Mehmet Sezgin Pepeler, Berna Savaş, Merve Pamukcuoğlu, Murat Törüner, Hakan Akbulut

    Amaç: Kolorektal kanser hücrelerinde vit D reseptör ekspresyonunun tespiti ve bu reseptör ekspresyon derecesi ile kolorektal kanser prognoz ve evresinin ilişkisi olup olmadığını tespit etmektir. Yöntem ve Gereç: Çalışmaya 2003-2009 tarihleri arasında Ankara Üniversitesi Tıp Fakültesi (AÜTF) Genel Cerrahi Bölümünde opere olmuş, AÜTF Patoloji Bölümünde Kolon ve Rektum kanseri (KRK) tanısı konulup medikal tedavisi AÜTF Tıbbi Onkoloji Bölümünce yapılan hastalar dahil edilmiştir.Vit D reseptörlerinin değerlendirilmesi için seçilen olguların Hematoksilen ve Eozin (H-E) kesitleri yeniden değerlendirildi. Bulgular: Vit D reseptörü pozitif olan hastalarda istatistiksel olarak anlamlı olmasa da medyan sağkalım reseptör negatif olanlara göre daha iyi bulunmuştur. Vitamin D reseptör (VDR) pozitif olanlarda medyan sağkalıma ulaşılamamıştır.5 yıllık sağkalım %69,4 oranında saptanmıştır. VDR negatif olanlarda medyan sağkalım 60 ay saptanmıştır. 5 yıllık sağkalım %32 oranında bulunmuştur. VDR pozitif ve negatif olanlar arasında medyan sağ kalım açısından istatiksel olarak anlamlı fark saptanmamıştır(p:0,053). Hastalıksız sağkalım için VDR'e göre anlamlı fark saptanmadı.VDR negatif olanlarda 5 yıllık hastalıksız sağkalım %56.8 bulunurken, VDR pozitif olanlarda %43.3 bulunmuştur (Şekil 2.2). Sonuç: VDR ekspresyonunun KRK prognozu üzerine olan etkisinin tek başına anlamlı olmadığı saptanmıştır. Reseptör ekspresyonu dışında reseptör polimorfizminin ve reseptörün etkilediği yolaklarda rol oynayan mutasyonların da prognozu belirlemede etkili olabileceği kanısına varılmıştır.


  • Peripheral and bone marrow CD34+ cell levels on chronic myeloproliferative disease

    by M. Pamukcuoglu, K. Acar, B. Celik, N. Akyurek, M.S. Pepeler, G.T. Sucak

    Purpose: The aim of the present study was to examine the relationship between peripheral CD34+ and bone marrow CD34+ levels and the clinicopathologic characteristics and laboratory parameters of myeloproliferative disease (MPD) patients. Patients and methods: A total of 103 MPD patients were enrolled in this study. We examined the relationship between bone marrow CD34+ and peripheral CD34+ levels and the patients’ clinicopathologic and laboratory parameters. Results: There were no significant correlations between the peripheral CD34+ levels and the JAK-2 V617F mutation, thrombosis, white blood cells (WBC), lactate dehydrogenase (LDH), transferrin saturation (TS), ferritin, or bone marrow cellularity. In addition, there were no significant correlations between bone marrow CD34+ levels and the JAK-2 V617F mutation, thrombosis, WBC, LDH, TS, ferritin, or bone marrow cellularity (P > 0.05). We did not identify any significant relationship between peripheral CD34+ and bone marrow CD34+ levels (P > 0.05). However, there were significant correlations between peripheral CD34+ levels and bone marrow fibrosis (P < 0.001), between bone marrow CD34+ levels and constitutional symptoms (P < 0.05), and between bone marrow CD34+ levels and bone marrow fibrosis (P < 0.001). Conclusion: We did not find any significant relationship between the clinicopathologic and laboratory characteristics and peripheral and bone marrow CD34+ cells from bone marrow fibrosis patients. There was also no significant relationship between bone marrow CD34+ cells and peripheral CD34+ cells. Some peripheral CD34+ cells may originate from the spleen rather than the bone marrow, which may given us different result of some parameters.